| アブストラクト | Tazobactam/piperacillin and meropenem are commonly used as an empiric treatment in patients with severe bacterial infections. However, few studies have investigated the cause of tazobactam/piperacillin- or meropenem-induced liver injury in them. Our objective was to evaluate the association between tazobactam/piperacillin or meropenem and liver injury in the intensive care unit patients. We evaluated the expression profiles of antibiotics-induced liver injury using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. Further, in the retrospective observational study, data of patients who initiated tazobactam/piperacillin or meropenem in the intensive care unit were extracted. In FAERS database, male, age, the fourth-generation cephalosporin, carbapenem, beta-lactam and beta-lactamase inhibitor combination, and complication of sepsis were associated with liver injury (p < 0.001). In the retrospective observational study, multivariate logistic regression analyses indicated that the risk factors for liver injury included male (p = 0.046), administration period >/= 7 days (p < 0.001), and alanine aminotransferase (p = 0.031). Not only administration period but also sex and alanine aminotransferase should be considered when clinicians conduct the monitoring of liver function in the patients receiving tazobactam/piperacillin or meropenem. |
|---|
| ジャーナル名 | Scientific reports |
|---|
| Pubmed追加日 | 2024/8/7 |
|---|
| 投稿者 | Shiraishi, Chihiro; Kato, Hideo; Ogura, Toru; Iwamoto, Takuya |
|---|
| 組織名 | Department of Pharmacy, Mie University Hospital, Tsu, 514-8507, Japan.;Division of Clinical Medical Science, Department of Clinical Pharmaceutics, Mie;University Graduate School of Medicine, Tsu, 514-8507, Japan.;hkato59@med.mie-u.ac.jp.;Clinical Research Support Center, Mie University Hospital, Tsu, 514-8507, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39107511/ |
|---|
